MARKET INTRODUCTION
Angiogenesis is a physiological process associated with the formation of the new blood vessel from existing blood vessels. The angiogenesis process is commonly categorized into two types, namely sprouting angiogenesis and intussusceptive angiogenesis. Sprouting angiogenesis is a fundamental vessel growth mechanism in which sequential steps regulate the new blood vessel's formation. Intussusceptive angiogenesis (also called splitting angiogenesis) is referred to as the new blood vessel created by the internal division of an existing blood vessel. Angiogenesis is mainly associated with a diverse set of conditions such as age-related macular degradation, rheumatoid arthritis, cancer, and psoriasis. The main focus of angiogenesis therapy is to shrink the existing tumor by an inhibitor or to meet the demand of under perfused region through generating new vessels by angiogenesis stimulator. Avastin (bevacizumab), Gleevec, Tarceva, and Iressa are some of the most extensive selling angiogenesis inhibitors worldwide.
MARKET DYNAMICS
The increase in the prevalence of cancer and recognition of therapeutic opportunities offered by oncology treatments and increasing investments in research and development will spur the demand for angiogenesis inhibitors and stimulators market. Additionally, technological advancement and increase in awareness, use of angiogenesis inhibitors in treatment of variety of indications will boost the market growth to significant extent over the forecast period. However, stringent government regulations and high cost of treatment impede the growth of the market in the forecasted period.
MARKET SCOPE
The "Global Angiogenesis Inhibitors and Stimulators Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of angiogenesis inhibitors and stimulators market with detailed market segmentation by product, application and geography. The global angiogenesis inhibitors and stimulators market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading angiogenesis inhibitors and stimulators market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global angiogenesis inhibitors and stimulators market is segmented on the product, and applications. Based on product, the global angiogenesis inhibitors and stimulators market is segmented into sprouting angiogenesis, and intussusceptive angiogenesis. Based on application, the global angiogenesis inhibitors and stimulators market is segmented into hospitals, clinics, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global angiogenesis inhibitors and stimulators market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The angiogenesis inhibitors and stimulators market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting angiogenesis inhibitors and stimulators market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Angiogenesis inhibitors and stimulators market in these regions.
MARKET PLAYERS
The reports cover key developments in the angiogenesis inhibitors and stimulators market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from angiogenesis inhibitors and stimulators market are anticipated to lucrative growth opportunities in the future with the rising demand for angiogenesis inhibitors and stimulators market in the global market. Below mentioned is the list of few companies engaged in the angiogenesis inhibitors and stimulators market.
The report also includes the profiles of key angiogenesis inhibitors and stimulators market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- F. Hoffmann-La Roche Ltd
- Abbott
- Bristol-Myers Squibb Company
- Amgen Inc
- AstraZeneca
- Novartis AG
- CASI Pharmaceuticals Inc.
- EYETECH DIGITAL SYSTEMS
- Johns Hopkins Medicine
- Pfizer Inc
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Angiogenesis Inhibitors And Stimulators Market - By Product
1.3.2 Angiogenesis Inhibitors And Stimulators Market - By Application
1.3.3 Angiogenesis Inhibitors And Stimulators Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANGIOGENESIS INHIBITORS AND STIMULATORS - GLOBAL MARKET OVERVIEW
6.2. ANGIOGENESIS INHIBITORS AND STIMULATORS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. SPROUTING ANGIOGENESIS
7.3.1. Overview
7.3.2. Sprouting Angiogenesis Market Forecast and Analysis
7.4. INTUSSUSCEPTIVE ANGIOGENESIS
7.4.1. Overview
7.4.2. Intussusceptive Angiogenesis Market Forecast and Analysis
8. ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
8.3.1. Overview
8.3.2. Hospitals Market Forecast and Analysis
8.4. CLINICS
8.4.1. Overview
8.4.2. Clinics Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Angiogenesis Inhibitors And Stimulators Market Overview
9.1.2 North America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis
9.1.3 North America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Product
9.1.4 North America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Application
9.1.5 North America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Countries
9.1.5.1 United States Angiogenesis Inhibitors And Stimulators Market
9.1.5.1.1 United States Angiogenesis Inhibitors And Stimulators Market by Product
9.1.5.1.2 United States Angiogenesis Inhibitors And Stimulators Market by Application
9.1.5.2 Canada Angiogenesis Inhibitors And Stimulators Market
9.1.5.2.1 Canada Angiogenesis Inhibitors And Stimulators Market by Product
9.1.5.2.2 Canada Angiogenesis Inhibitors And Stimulators Market by Application
9.1.5.3 Mexico Angiogenesis Inhibitors And Stimulators Market
9.1.5.3.1 Mexico Angiogenesis Inhibitors And Stimulators Market by Product
9.1.5.3.2 Mexico Angiogenesis Inhibitors And Stimulators Market by Application
9.2. EUROPE
9.2.1 Europe Angiogenesis Inhibitors And Stimulators Market Overview
9.2.2 Europe Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis
9.2.3 Europe Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Product
9.2.4 Europe Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Application
9.2.5 Europe Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Angiogenesis Inhibitors And Stimulators Market
9.2.5.1.1 Germany Angiogenesis Inhibitors And Stimulators Market by Product
9.2.5.1.2 Germany Angiogenesis Inhibitors And Stimulators Market by Application
9.2.5.2 France Angiogenesis Inhibitors And Stimulators Market
9.2.5.2.1 France Angiogenesis Inhibitors And Stimulators Market by Product
9.2.5.2.2 France Angiogenesis Inhibitors And Stimulators Market by Application
9.2.5.3 Italy Angiogenesis Inhibitors And Stimulators Market
9.2.5.3.1 Italy Angiogenesis Inhibitors And Stimulators Market by Product
9.2.5.3.2 Italy Angiogenesis Inhibitors And Stimulators Market by Application
9.2.5.4 Spain Angiogenesis Inhibitors And Stimulators Market
9.2.5.4.1 Spain Angiogenesis Inhibitors And Stimulators Market by Product
9.2.5.4.2 Spain Angiogenesis Inhibitors And Stimulators Market by Application
9.2.5.5 United Kingdom Angiogenesis Inhibitors And Stimulators Market
9.2.5.5.1 United Kingdom Angiogenesis Inhibitors And Stimulators Market by Product
9.2.5.5.2 United Kingdom Angiogenesis Inhibitors And Stimulators Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Angiogenesis Inhibitors And Stimulators Market Overview
9.3.2 Asia-Pacific Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis
9.3.3 Asia-Pacific Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Angiogenesis Inhibitors And Stimulators Market
9.3.5.1.1 Australia Angiogenesis Inhibitors And Stimulators Market by Product
9.3.5.1.2 Australia Angiogenesis Inhibitors And Stimulators Market by Application
9.3.5.2 China Angiogenesis Inhibitors And Stimulators Market
9.3.5.2.1 China Angiogenesis Inhibitors And Stimulators Market by Product
9.3.5.2.2 China Angiogenesis Inhibitors And Stimulators Market by Application
9.3.5.3 India Angiogenesis Inhibitors And Stimulators Market
9.3.5.3.1 India Angiogenesis Inhibitors And Stimulators Market by Product
9.3.5.3.2 India Angiogenesis Inhibitors And Stimulators Market by Application
9.3.5.4 Japan Angiogenesis Inhibitors And Stimulators Market
9.3.5.4.1 Japan Angiogenesis Inhibitors And Stimulators Market by Product
9.3.5.4.2 Japan Angiogenesis Inhibitors And Stimulators Market by Application
9.3.5.5 South Korea Angiogenesis Inhibitors And Stimulators Market
9.3.5.5.1 South Korea Angiogenesis Inhibitors And Stimulators Market by Product
9.3.5.5.2 South Korea Angiogenesis Inhibitors And Stimulators Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Angiogenesis Inhibitors And Stimulators Market Overview
9.4.2 Middle East and Africa Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis
9.4.3 Middle East and Africa Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Angiogenesis Inhibitors And Stimulators Market
9.4.5.1.1 South Africa Angiogenesis Inhibitors And Stimulators Market by Product
9.4.5.1.2 South Africa Angiogenesis Inhibitors And Stimulators Market by Application
9.4.5.2 Saudi Arabia Angiogenesis Inhibitors And Stimulators Market
9.4.5.2.1 Saudi Arabia Angiogenesis Inhibitors And Stimulators Market by Product
9.4.5.2.2 Saudi Arabia Angiogenesis Inhibitors And Stimulators Market by Application
9.4.5.3 U.A.E Angiogenesis Inhibitors And Stimulators Market
9.4.5.3.1 U.A.E Angiogenesis Inhibitors And Stimulators Market by Product
9.4.5.3.2 U.A.E Angiogenesis Inhibitors And Stimulators Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Angiogenesis Inhibitors And Stimulators Market Overview
9.5.2 South and Central America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis
9.5.3 South and Central America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Product
9.5.4 South and Central America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Application
9.5.5 South and Central America Angiogenesis Inhibitors And Stimulators Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Angiogenesis Inhibitors And Stimulators Market
9.5.5.1.1 Brazil Angiogenesis Inhibitors And Stimulators Market by Product
9.5.5.1.2 Brazil Angiogenesis Inhibitors And Stimulators Market by Application
9.5.5.2 Argentina Angiogenesis Inhibitors And Stimulators Market
9.5.5.2.1 Argentina Angiogenesis Inhibitors And Stimulators Market by Product
9.5.5.2.2 Argentina Angiogenesis Inhibitors And Stimulators Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANGIOGENESIS INHIBITORS AND STIMULATORS MARKET, KEY COMPANY PROFILES
12.1. ABBOTT
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BRISTOL-MYERS SQUIBB COMPANY
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. F. HOFFMANN-LA ROCHE LTD
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. AMGEN INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ASTRAZENECA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. NOVARTIS AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PFIZER INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. CASI PHARMACEUTICALS INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. EYETECH DIGITAL SYSTEMS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. JOHNS HOPKINS MEDICINE
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. F. Hoffmann-La Roche Ltd
2. Abbott
3. Bristol-Myers Squibb Company
4. Amgen Inc
5. AstraZeneca
6. Novartis AG
7. CASI Pharmaceuticals Inc.
8. EYETECH DIGITAL SYSTEMS
9. Johns Hopkins Medicine
10. Pfizer Inc